In this episode,Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections caused by NDM-producing Enterobacterales, including: Ambler classification of β-lactamasesMechanisms of resistance2023 IDSA guidance recommendationsThe latest clinical data by antimicrobial regimen:Ceftazidime/avibactam and aztreonamCefiderocolInvestigational aztreonam/avibactamClinical case of NDM-producing E. coli with pan-β-lactam resistanceProgram Director:Trevor Van Schooneveld, MD, FSHEA, FACP Professor, Division of Infectious DiseasesProgram Director, Infectious Diseases FellowshipMedical Director, Antimicrobial Stewardship ProgramUniversity of Nebraska Medical CenterOmaha, NebraskaFaculty:Emily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of PharmacyUniversity of Maryland School of PharmacyID Clinical Pharmacy SpecialistUniversity of Maryland Medical CenterBaltimore, MarylandLaila Woc-Colburn, MDAssociate ProfessorDivision of Infectious DiseasesEmory University School of Medicine Atlanta, GeorgiaContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program:https://bit.ly/40HyvPy